The deal, worth $700,000 plus a royalty stream of 12.5%, covers Australia and New Zealand.
Cell-Innovations will market the stromal vascular fraction (SVF) manufacturing technology of IntelliCell BioSciences in Australia and New Zealand, under a license agreement that calls for a one-time payment of $700,000 and a royalty stream of 12.5% of net sales.
IntelliCell’s technology is a nonenzymatic method for deriving SVF containing adult stem cells from 60 cc’s of adipose tissue. According to the company, the technology generates between half billion to 1.4 billion SVF cells, about 10–20 times greater than present-day enzyme-based methods.
Cell-Innovations and IntelliCell also say they will assist Macquarie Stem Cells, a company of Cell-Innovations director Ralph Bright, to establish IntelliCell Centers of Excellence where doctors can treat their patients.
